Arca
Skip to content
Tools
Tools

DRD2, DRD3: Dopamine receptors; D2 & D3

Selectivity group in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on DRD2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Amisulpride

Phase 31

  • Pardoprunox

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      AmisulprideApprovedLXO IrelandSmall moleculeAntagonistDopamine receptors; D2 & D3 antagonist9
      PardoprunoxPhase 3SolvaySmall moleculePartial agonistDopamine receptors; D2 & D3 partial agonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Sequential Treatment Approaches for Treatment-Resistant SchizophreniaAmisulpridePhase 3RecruitingShanghai Mental Health CenterNov 5, 2026
      Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic SurgeryAmisulprideNot applicableNot yet recruitingQianfoshan HospitalOct 23, 2026
      Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic SurgeryAmisulprideNot applicableNot yet recruitingSir Run Run Shaw HospitalJun 8, 2026
      Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic SurgeryAmisulpride—Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineApr 28, 2026
      Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.AmisulpridePhase 2RecruitingLB Pharmaceuticals Inc.Mar 27, 2026
      Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical SettingsAmisulprideEarly phase 1Not yet recruitingStanford UniversityJan 16, 2026
      Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological SurgeryAmisulpridePhase 2Active, not recruitingInstituto do Cancer do Estado de São PauloMar 20, 2025
      Magnetic Seizure Therapy for Psychotic DisordersAmisulprideNot applicableRecruitingShanghai Jiao Tong University School of MedicineSep 3, 2024

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095169, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.